American Century Companies Inc. Purchases 246,063 Shares of Gilead Sciences, Inc. $GILD

Key Points

• American Century Companies Inc. increased its stake in Gilead Sciences by 12.0%, acquiring an additional 246,063 shares during the first quarter, bringing its total holdings to approximately 2.3 million shares worth $257.4 million.
• The biopharmaceutical company recently declared a quarterly dividend of $0.79 per share, with an annualized yield of 2.7%, to be paid on September 29th.
• Gilead Sciences' latest earnings report showed a profit of $2.01 per share for the quarter, exceeding estimates, alongside revenue of $7.08 billion, marking a year-over-year increase of 1.4%.

American Century Companies Inc. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,297,580 shares of the biopharmaceutical company's stock after purchasing an additional 246,063 shares during the period. American Century Companies Inc. owned 0.18% of Gilead Sciences worth $257,444,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nissay Asset Management Corp Japan ADV increased its holdings in shares of Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after acquiring an additional 14,009 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after acquiring an additional 109 shares during the last quarter. Mufg Securities Americas Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter valued at about $1,699,000. Capital International Inc. CA increased its holdings in shares of Gilead Sciences by 23.8% during the 4th quarter. Capital International Inc. CA now owns 312,209 shares of the biopharmaceutical company's stock valued at $28,839,000 after acquiring an additional 60,035 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. acquired a new position in shares of Gilead Sciences during the 1st quarter valued at about $11,688,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $0.01 during trading hours on Tuesday, reaching $117.98. The stock had a trading volume of 6,154,639 shares, compared to its average volume of 8,328,695. The business's fifty day moving average is $111.98 and its two-hundred day moving average is $108.64. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a market cap of $146.39 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a twelve month low of $74.34 and a twelve month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the company earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. UBS Group raised their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a report on Tuesday. Finally, Royal Bank Of Canada raised their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $115.39.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer owned 162,610 shares in the company, valued at $18,054,588.30. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer directly owned 605,725 shares in the company, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 110,000 shares of company stock worth $12,349,790 over the last 90 days. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.